Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450

Biochemical Pharmacology

Volumn 51, Issue 5, 1996, Pages 591-598

  Pichard, Lydiane ^a   Domergue, Jacques ^b   Fourtanier, Gilles ^c   Koch, Patrick ^d   Schran, Horst F ^d   Maurel, Patrick ^a  

^a CNRS   (France)

^b HÔPITAL SAINT ELOI   (France)

^c CHU RANGUEIL   (France)

^d Sandoz Pharma Ltd   (Switzerland)

Author keywords

Cyclosporin G; Drug interactions; Human CYP; Immunosuppressor; Oxidative metabolism

Indexed keywords

AZATADINE; BETA NAPHTHOFLAVONE; CARBAMAZEPINE; COMPLEMENTARY DNA; COUMARIN; CYCLOSPORIN A; CYCLOSPORIN G; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; ENZYME ANTIBODY; ENZYME INDUCING AGENT; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; OXIDOREDUCTASE; OXOMEMAZINE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; PROPRANOLOL; RIFAMPICIN; SULFAPHENAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN; UNINDEXED DRUG; VIRGINIAMYCIN;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LIVER CELL CULTURE; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

ADULT; AGED; BIOTRANSFORMATION; CELLS, CULTURED; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES;

EID: 0029876284     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(95)02175-2     Document Type: Article

References (34)

1. Borel JF, The cyclosporines. Transplant Proc 21: 810-815, 1989.
2. Jeffery JR, Cyclosporine analogues. Clin Biochem 24: 15-21, 1991.
3. Hoyt EG, Hagberg RC, Billingham ME, Baldwin JC and Jamieson SW, Analysis of the immunosuppressive and nephrotoxic effects of cyclosporine G. J Heart Transplant 7: 111-117, 1988.
4. Grant D, Zhong R, Stiller C, Wallace C, Keown P, Duff J, A comparison of cyclosporine (cyclosporine G) in a rat renal allograft model. Transplantation 44: 9-12, 1987.
5. Hagberg RC, Hoyt EG, Billingham ME, Sibley RK, Starnes VA, Baldwin JC, Comparison of cyclosporine A and G with and without azathioprine regarding immunosuppressive efficacy, toxicity and pharmacokinetics in Lewis rats. J Heart Transplant 7: 359-369, 1988.
6. Wenk M, Bindschedler M, Costa E, Zuber M, Vozeh S, Thiel G, Abisch E, Keller HP, Beveridge T, Follath F, Pharmacokinetics of cyclosporine G in patients with renal failure. Transplantation 45: 558-561, 1988.
7. 2 cyclosporine) in blood and plasma. Clin Chem 39: 213-217, 1993.
8. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P, Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450 IIIA gene subfamily. Drug Metab Dispos 17: 197-207, 1989.
9. Kronbach T, Fischer V, Meyer UA, Cyclosporine metabolism in human liver: identification of a cytochrome P450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporin with other drugs. Clin Pharmacol Ther 43: 630-635, 1988.
10. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P, Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18: 595-606, 1990.
11. Maurel P, Pichard L, Greuet J, Muntane J, Ourlin JC, Daujat M, Inhibition and repression of CYP3A4 in primary cultures of human hepatocytes. Comparative analysis with clinical observations. In: Proceedings of the 10th International Symposium on Microsomes and Drug Oxidations, Toronto, Canada, 18-21 July 1994, pp. 188-190, 1994.
12. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P, Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47: 410-418, 1995.
13. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 6: 752-758, 1992.
14. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P, Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41: 1047-1055, 1992.
15. Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, Maurel P, Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99: 737-747, 1990.
16. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, Lesca P, Domergue J, Joyeux H, Fourtanier G, Maurel P, Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 269: 384-392, 1994.
17. Dalet-Beluche I, Boulenc X, Fabre G, Maurel P, Bonfils C, Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross-reactivity with human forms. Eur J Biochem 204: 641-648, 1992.
18. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA, Antibodies against human cytochrome P450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85: 8256-8260, 1988.
19. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Harwick JP, Meyer UA, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442-446, 1988.
20. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI, Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
21. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, McManus ME, Relationship between phenytoin and tolbutamide hydroxylation in human liver microsomes. Br J Clin Pharmacol 31: 125-130, 1991.
22. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF, Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247: 242-247, 1988.
23. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T, Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13: 1789-1794, 1992.
24. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian PS, Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82: 6310-6314, 1985.
25. Gillam EMJ, Reilly PEB, Phenacetin O-deethylation by human liver microsomes: kinetics and propranolol inhibition. Xenobiotica 18: 95-104, 1988.
26. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP, Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 241: 1112-1119, 1987.
27. Ortiz de Montellano PR, Chan WK, Tuck SF, Kaikaus RM, Bass NM, Peterson JA, Mechanism-based probe of the topology and function of fatty acid hydroxylases. FASEB J 6: 695-699, 1992.
28. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH, Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253: 387-394, 1990.
29. Aoyama T, Yamano S, Waxman D et al., Cytochrome P450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 264: 10388-10395, 1989.
30. Turgeon KD, Leichtman AB, Blake DS, Schmouder RL, Lown KS, Annesley TM, Watkins PB, Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients. Transplantation 57: 1736-1741, 1994.
31. Ptachcinski RJ, Venkataramanan R, Burkart GJ, Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11: 107-132, 1986.
32. Kolars JC, Awni WM, Merion RM, Watkins PB, First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488-1490, 1991.
33. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB, Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871-1878, 1992.
34. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB, Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 22: 947-955, 1994.